{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:53:40Z","timestamp":1792630420352,"version":"4.5.0"},"reference-count":398,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Med. Chem."],"published-print":{"date-parts":[[2020,5,28]]},"DOI":"10.1021\/acs.jmedchem.9b01701","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T22:37:34Z","timestamp":1578955054000},"page":"5031-5073","source":"Crossref","is-referenced-by-count":96,"title":["The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease"],"prefix":"10.1021","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7917-1459","authenticated-orcid":true,"given":"F. Anthony","family":"Romero","sequence":"first","affiliation":[{"name":"Terns Pharmaceuticals, 1065 E. Hillsdale Blvd., Suite\r100, Foster City, California 94404, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Jones","sequence":"additional","affiliation":[{"name":"Terns Pharmaceuticals, 1065 E. Hillsdale Blvd., Suite\r100, Foster City, California 94404, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzi","family":"Xu","sequence":"additional","affiliation":[{"name":"Terns Pharmaceuticals, 1065 E. Hillsdale Blvd., Suite\r100, Foster City, California 94404, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Fenaux","sequence":"additional","affiliation":[{"name":"Terns Pharmaceuticals, 1065 E. Hillsdale Blvd., Suite\r100, Foster City, California 94404, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall L.","family":"Halcomb","sequence":"additional","affiliation":[{"name":"Terns Pharmaceuticals, 1065 E. Hillsdale Blvd., Suite\r100, Foster City, California 94404, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"ref1\/cit1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367"},{"key":"ref2\/cit2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.11.039"},{"key":"ref3\/cit3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.07.019"},{"key":"ref4\/cit4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431"},{"key":"ref5\/cit5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.036"},{"key":"ref6\/cit6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01377.x"},{"key":"ref7\/cit7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25889"},{"key":"ref8\/cit8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.09.003"},{"key":"ref9\/cit9","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9679-0"},{"key":"ref10\/cit10","first-page":"64","volume":"36","author":"Glass L. M.","year":"2019","journal-title":"Fed. Pract."},{"key":"ref11\/cit11","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2014.06.015"},{"key":"ref12\/cit12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01718.x"},{"key":"ref13\/cit13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27368"},{"key":"ref14\/cit14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"ref15\/cit15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.014"},{"key":"ref16\/cit16","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.20.5.0380"},{"key":"ref17\/cit17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.02.019"},{"key":"ref18\/cit18","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2016.11.009"},{"key":"ref19\/cit19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0306981100"},{"key":"ref20\/cit20","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000252790.70572.0c"},{"key":"ref21\/cit21","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv331"},{"key":"ref22\/cit22","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50015"},{"key":"ref23\/cit23","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M210062200"},{"key":"ref24\/cit24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2273.1989.tb00383.x"},{"key":"ref25\/cit25","doi-asserted-by":"publisher","DOI":"10.1021\/jm9903601"},{"key":"ref26\/cit26","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2007.10.002"},{"key":"ref27\/cit27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929"},{"key":"ref28\/cit28","doi-asserted-by":"publisher","DOI":"10.1021\/jm950395a"},{"key":"ref29\/cit29","doi-asserted-by":"publisher","DOI":"10.1021\/jm010964g"},{"key":"ref30\/cit30","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932030-00002"},{"key":"ref31\/cit31","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1061"},{"key":"ref32\/cit32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2007.05.007"},{"key":"ref33\/cit33","unstructured":"Cymabay https:\/\/ir.cymabay.com\/press-releases\/detail\/476\/cymabay-therapeutics-halts-clinical-development-of-seladelpar (accessed Nov 26, 2019)."},{"key":"ref34\/cit34","doi-asserted-by":"publisher","DOI":"10.1210\/me.2013-1427"},{"key":"ref35\/cit35","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.01.038"},{"key":"ref36\/cit36","unstructured":"Genfit https:\/\/www.genfit.com\/press-release\/genfit-positive-36-month-dsmb-recommendation-for-continuation-of-phase-3-resolve-it-study-of-elafibranor-in-nash\/ (accessed Sept 25, 2019)."},{"key":"ref37\/cit37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19072069"},{"key":"ref38\/cit38","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M700330-JLR200"},{"key":"ref39\/cit39","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c120023"},{"key":"ref40\/cit40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20040964"},{"key":"ref41\/cit41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI21025"},{"key":"ref42\/cit42","doi-asserted-by":"publisher","DOI":"10.1007\/s40495-017-0085-2"},{"key":"ref43\/cit43","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)00062-3"},{"key":"ref44\/cit44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI76738"},{"key":"ref45\/cit45","doi-asserted-by":"publisher","DOI":"10.2337\/db16-0663"},{"key":"ref46\/cit46","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.08.057"},{"key":"ref47\/cit47","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10166"},{"key":"ref48\/cit48","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-128X(96)00119-5"},{"key":"ref49\/cit49","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/S0022-2275(20)39933-8","volume":"35","author":"Roda A.","year":"1994","journal-title":"J. Lipid Res."},{"key":"ref50\/cit50","doi-asserted-by":"publisher","DOI":"10.1021\/jm025529g"},{"key":"ref51\/cit51","unstructured":"Intercept http:\/\/ir.interceptpharma.com\/news-releases\/news-release-details\/intercept-announces-positive-topline-results-pivotal-phase-3 (accessed Nov 26, 2019)."},{"key":"ref52\/cit52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2019.06.017"},{"key":"ref53\/cit53","doi-asserted-by":"publisher","DOI":"10.1172\/JCI64551"},{"key":"ref54\/cit54","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2016.00646"},{"key":"ref55\/cit55","unstructured":"Wang, G.; Or, Y. S.; Shen, R.; Long, J.; Dai, P.; Xing, X.; He, J. Bile Acid Derivatives as PXR\/TGR5 Agonists and Methods of Use Thereof. International Patent WO2016086218, 2016."},{"key":"ref56\/cit56","doi-asserted-by":"publisher","DOI":"10.11648\/j.ijg.20190301.12"},{"key":"ref57\/cit57","doi-asserted-by":"crossref","unstructured":"Ahmad, A.; Sanderson, K.; Dickerson, D.; Adda, N. Pharmacokinetics, Pharmacodynamics, and Safety of EDP-305 in Healthy and Presumptive NAFLD Subjects. Presented at the European Associate for the Study of the Liver International Liver Conference, Paris, France, April 11\u201315, 2018; FRI-489.","DOI":"10.1016\/S0168-8278(18)31427-2"},{"key":"ref58\/cit58","unstructured":"Enanta https:\/\/www.enanta.com\/investors\/news-releases\/press-release\/2019\/Enanta-Announces-Positive-Results-of-ARGON-1-Study-of-its-lead-FXR-Agonist-EDP-305-for-the-Treatment-of-NASH\/default.aspx (accessed Sept 25, 2019)."},{"key":"ref59\/cit59","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/164_2019_232","volume-title":"Bile Acids And Their Receptors","author":"Gege C.","year":"2019"},{"key":"ref60\/cit60","doi-asserted-by":"publisher","DOI":"10.1021\/jm0002127"},{"key":"ref61\/cit61","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01161"},{"key":"ref62\/cit62","doi-asserted-by":"crossref","unstructured":"Klucher, K.; Wang, Y.; Halcomb, R.; Fenaux, M. A Novel Farnesoid X Receptor Agonist, TERN-101, Reduces Liver Steatosis, Inflammation, Ballooning and Fibrosis in a Murine Model of Non-Alcoholic Steatohepatitis. Presented at the European Associate for the Study of the Liver International Liver Conference, Vienna, Austria, April 10\u201314, 2019; FRI-313.","DOI":"10.1016\/S0618-8278(19)31056-4"},{"key":"ref63\/cit63","unstructured":"TERN-101 Licensing. https:\/\/www.businesswire.com\/news\/home\/20180404005033\/en\/Terns-Pharmaceuticals-Acquires-Global-Exclusive-Rights-Develop (accessed Sept 25, 2019)."},{"key":"ref64\/cit64","unstructured":"Terns\nPharmaceuticals: TERN-101. https:\/\/www.ternspharma.com\/6-13-19-terns-pharmaceuticals-initiates-a-phase-1-clinical-trial-of-tern-101 (accessed Sept 25, 2019)."},{"key":"ref65\/cit65","unstructured":"Kinzel, O.; Steeneck, C.; Kremoser, C. Novel FXR (NR1H4) Binding and Activity Modulating Compounds. International Patent WO2013007387, 2013."},{"key":"ref66\/cit66","doi-asserted-by":"crossref","unstructured":"Hambruch, E.; Liles, J.; Kinzel, O.; Birkel, M.; French, D.; Hollenback, D.; Djedjos, S.; Kirby, B.; Hornherger, M.; Walkins, W.; Kremoser, C. How to Develop a Differentiated FXR Agonist: GS-9674 Shows a Reduced Side Effect Profile in Mice, Monkeys and Human Phase 1 Studies Compared to Its Predecessor Px-102. Presented at the European Associate for the Study of the Liver International Liver Conference, Vienna, Austria, April 10\u201314, 2019; FRI-303.","DOI":"10.1016\/S0618-8278(19)31046-1"},{"key":"ref67\/cit67","unstructured":"Patel, K.; Harrison, S. A.; Trotter, J. F.; Herring, R.; Rojter, S. E.; Kayali, Z.; Shiffman, M. L.; Freilich, B. L.; Lawitz, E. J.; Harting, E.; Nguyen, T.; Chung, C.; Subramanian, M.; Myers, R. P.; Middleton, M. S.; Rinella, M. E. M.; Noureddin, M. The Non-Steroidal FXR Agonist GS-9674 Leads to Significant Reductions in Hepatic Steatosis, Serum Bile Acids, and Liver Biochemistry in a Phase 2, Randomized, Placebo-Controlled Trial of Patients with NASH. Presented at the American Association for the Study of Liver Diseases, San Francisco, USA, November 9\u201313, 2018; 736."},{"key":"ref68\/cit68","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00907"},{"key":"ref69\/cit69","doi-asserted-by":"crossref","unstructured":"Lucas, K. J.; Lopez, P.; Lawitz, E. J.; Sheikh, A.; Aizenberg, D.; Hsia, S.; Goh, G. B. B.; Vierling, J. M.; Frias, J. P.; White, J.; Eguchi, Y.; Lazas, D.; Neff, G.; Yoneda, M.; Augustin, S.; Kim, W.; Loeffler, J.; Schaefer, F. A.; Lamle, S.; Martic, M.; Brass, C.; Sanyal, A. Tropifexor, a Highly Potent FXR Agonist, Produces Robust and Dose-Dependent Reductions in Hepatic Fat and Serum Alanine Aminotransferase in Patients with Fibrotic NASH after 12 Weeks of Therapy: FLIGHT-FXR Part C Interim Results. Presented at the American Association for the Study of Liver Diseases, Boston, USA, November 13\u201317, 2019, LO4.","DOI":"10.1016\/j.dld.2019.12.129"},{"key":"ref70\/cit70","unstructured":"Chianelli, D.; Liu, X.; Molteni, V.; Nelson, J.; Roland, J. Compositions and Methods for Modulating Farnesoid X Receptors. International Patent WO2015069666, 2015."},{"key":"ref71\/cit71","doi-asserted-by":"crossref","unstructured":"Laffitte, B.; Liu, B.; Kim, Y.; Bao, D.; Zoll, J.; Wu, X.; Badman, M.; Nelson, J.; Rucker, P.; Liu, X.; Chianelli, D.; Tully, D.; Roland, J.; Molteni, V. Development of LMB763, a Novel, Orally Bioavailable, Clinical Farnesoid X Receptor Agonist for the Treatment of Non-Alcoholic Steatohepatitis and Hepatobiliary Disorders. Presented at the European Associate for the Study of the Liver International Liver Conference, Amsterdam, The Netherlands, April 19\u201323, 2017; THU-378.","DOI":"10.1016\/S0168-8278(17)30609-8"},{"key":"ref72\/cit72","unstructured":"Roche, D.; Kober, G. M.; Contard, F.; Christmann-Franck, S. Benzofurane, Benzothiophene, Benzothiazol Derivatives as FXR Modulators. International Patent WO2009127321, 2009."},{"key":"ref73\/cit73","unstructured":"Metacrine https:\/\/www.globenewswire.com\/news-release\/2019\/05\/29\/1856242\/0\/en\/Metacrine-Reports-Positive-Interim-Results-with-Sustained-FXR-Agonist-in-NASH-Patients.html (accessed Sept 25, 2019)."},{"key":"ref74\/cit74","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2017.04.006"},{"key":"ref75\/cit75","doi-asserted-by":"publisher","DOI":"10.1210\/en.2008-1795"},{"key":"ref76\/cit76","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60047"},{"key":"ref77\/cit77","doi-asserted-by":"publisher","DOI":"10.1210\/er.2008-0019"},{"key":"ref78\/cit78","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.2001.81.3.1097"},{"key":"ref79\/cit79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2006.05.008"},{"key":"ref80\/cit80","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(02)00947-2"},{"key":"ref81\/cit81","doi-asserted-by":"publisher","DOI":"10.2217\/17460875.2.6.641"},{"key":"ref82\/cit82","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2018.10"},{"key":"ref83\/cit83","doi-asserted-by":"publisher","DOI":"10.1021\/jm4019299"},{"key":"ref84\/cit84","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-5521(98)90168-5"},{"key":"ref85\/cit85","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1633737100"},{"key":"ref86\/cit86","doi-asserted-by":"publisher","DOI":"10.1021\/jm2004706"},{"key":"ref87\/cit87","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.07.056"},{"key":"ref88\/cit88","unstructured":"Harrison, S.; Guy, C.; Bashir, M.; Frias, J.; Alkhouri, N.; Baum, S.; Taub, R.; Moylan, C.; Bansal, M.; Neuschwander-Tetri, B. A.; Moussa, S. In a Placebo-Controlled 36-Week Phase 2 Trial, Treatment with MGL-3196 Compared with Placebo Results in Significant Reductions in Hepatic Fat (MRI-PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic Lipids, and Improvement in Nash on Serial Liver Biopsy. Presented at the American Association for the Study of Liver Diseases, San Francisco, USA, November 9\u201313, 2018, ABS 14."},{"key":"ref89\/cit89","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32517-6"},{"key":"ref90\/cit90","doi-asserted-by":"publisher","DOI":"10.1021\/jm800824d"},{"key":"ref91\/cit91","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702759104"},{"key":"ref92\/cit92","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.021642"},{"key":"ref93\/cit93","doi-asserted-by":"crossref","unstructured":"Lombda, R.; Neutel, J.; Bernard, D.; Severance, R.; Mohseni, R.; Dao, M.; Saini, S.; Margaritescu, C.; Homer, K.; Tran, B.; Mancini, M.; Masume, H.; Lian, B. VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial. Presented at the  American Association for the Study of Liver Diseases, San Francisco, USA, November 9\u201313, 2018; LB-4.","DOI":"10.1016\/S0618-8278(19)30266-X"},{"key":"ref94\/cit94","doi-asserted-by":"publisher","DOI":"10.1055\/a-0623-2909"},{"key":"ref95\/cit95","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.04.024"},{"key":"ref96\/cit96","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M808818200"},{"key":"ref97\/cit97","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-0887-1_12"},{"key":"ref98\/cit98","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.00419"},{"key":"ref99\/cit99","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15433"},{"key":"ref100\/cit100","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0208"},{"key":"ref101\/cit101","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30590"},{"key":"ref102\/cit102","unstructured":"Harrison, S. A.; Banerjee, R.; Trotter, J. F.; Paredes, A. H.; Army, B.; Jaros, M.; Ling, L.; DePaoli, A. 12 Weeks of NGM282 Therapy Produced Significant and Sustained Reduction in cT1 in Patients with Nonalcoholic Steatohepatitis. Presented at the American Association for the Study of Liver Diseases, Boston, USA, November 13\u201317, 2019, 1747."},{"key":"ref103\/cit103","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30474-4"},{"key":"ref104\/cit104","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31785-9"},{"key":"ref105\/cit105","unstructured":"Kopec, K. K.; Liu, P. M. Mutant FGF-21 Peptide Conjugates and Uses Thereof. International Patent WO2019043457, 2019."},{"key":"ref106\/cit106","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(73)91137-6"},{"key":"ref107\/cit107","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(74)90058-7"},{"key":"ref108\/cit108","doi-asserted-by":"publisher","DOI":"10.1021\/jm401994c"},{"key":"ref109\/cit109","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0019-2"},{"key":"ref110\/cit110","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4889(89)90014-1"},{"key":"ref111\/cit111","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M606357200"},{"key":"ref112\/cit112","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.01540"},{"key":"ref113\/cit113","doi-asserted-by":"crossref","first-page":"22162","DOI":"10.1016\/S0021-9258(17)31770-2","volume":"269","author":"Ha J.","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref114\/cit114","doi-asserted-by":"publisher","DOI":"10.1111\/febs.13698"},{"key":"ref115\/cit115","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00011.2008"},{"key":"ref116\/cit116","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.508747"},{"key":"ref117\/cit117","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.05.005"},{"key":"ref118\/cit118","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00866"},{"key":"ref119\/cit119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.04.009"},{"key":"ref120\/cit120","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01344"},{"key":"ref121\/cit121","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.7b00417"},{"key":"ref122\/cit122","doi-asserted-by":"publisher","DOI":"10.1126\/science.aah5582"},{"key":"ref123\/cit123","unstructured":"Bolze, S.; Hallakou-Bozec, S.; Roden, M.; Roux, J. PXL770, A Novel Direct Ampk Activator, Improves Metabolic Disorders in a Diet-Induced Mice Model of Obesity and Diabetes. Presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany, September 12\u201316, 2016, Oral Presentation #113."},{"key":"ref124\/cit124","unstructured":"Gluais-Dagorn, P., Fouqueray, P.; Bolze, S.; Hallakou-Bozec, S. PXL770, a New Direct AMP Kinase Activator, Demonstrates Promising Effects for Treatment of Non-Alcoholic Steatohepatitis. Presented at the Global NASH Congress, London, UK, February 26\u201327, 2018, Poster #4."},{"key":"ref125\/cit125","unstructured":"Cravo, D.; Hallakou-Bozec, S.; Bolze, S.; Lepifre, F.; Faveriel, L. Thienopyridone Dervatives Useful as Activators of AMPK. WO2014001554, 2014."},{"key":"ref126\/cit126","unstructured":"Cravo, D.; Hallakou-Bozec, S.; Bolze, S.; Lepifre, F. Thieno[2,3-b]pyidinedione Activators of AMPK and Therapeutic Uses Thereof. International Patent WO2011080277, 2011."},{"key":"ref127\/cit127","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R800079-JLR200"},{"key":"ref128\/cit128","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.nutr.28.061807.155434"},{"key":"ref129\/cit129","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.nutr.17.1.77"},{"key":"ref130\/cit130","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2018.05.055"},{"key":"ref131\/cit131","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01547"},{"key":"ref132\/cit132","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2007.01.022"},{"key":"ref133\/cit133","doi-asserted-by":"publisher","DOI":"10.1021\/jm060484v"},{"key":"ref134\/cit134","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00024.2006"},{"key":"ref135\/cit135","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60408-4"},{"key":"ref136\/cit136","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30206"},{"key":"ref137\/cit137","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.07.009"},{"key":"ref138\/cit138","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1520686113"},{"key":"ref139\/cit139","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.027"},{"key":"ref140\/cit140","doi-asserted-by":"crossref","unstructured":"Lawitz, E.; Gane, E.; Ruane, P.; Herring, R.; Younes, Z. H.; Kwo, P.; Zhang, J.; Jia, C.; Chuang, J.; McColgan, B.; Chung, C.; Subramanian, M.; Myers, R.; Middleton, M.; Li, K.; Hellerstein, M.; Noureddin, M.; Harrison, S.; Loomba, R. A Combination of the ACC Inhibitor GS-0976 and the Nonsteroidal FXR Agonist GS-9674 Improves Hepatic Steatosis, Biochemistry, and Stiffness in Patients with Non-Alcoholic Steatohepatitis. Presented at the European Associate for the Study of the Liver International Liver Conference, Vienna, Austria, April 10\u201314, 2019; SAT-352.","DOI":"10.1016\/S0618-8278(19)31582-8"},{"key":"ref141\/cit141","unstructured":"Didiuk, M. T.; Dow, R. L.; Griffith, D. A. N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors. International Patent WO2012042433, 2012."},{"key":"ref142\/cit142","unstructured":"Fernando, D.; Lacasse, S. M.; Wiglesworth, K. Crystalline 2-Amino-2-(hydroxymethyl)propane-1,3-diol Salt ff 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4\u2019-piperidine]-1\u2019-carbonyl)-6-methoxypyridin-2-yl)benzoic Acid. International Patent WO2019102311, 2019."},{"key":"ref143\/cit143","unstructured":"Bagley, S. W.; Dow, R. L.; Griffith, D. A.; Smith, A. C. N1\/N2-Lactam Acetyl-CoA Carboxylase Inhibitors. International Patent WO2012056372, 2012."},{"key":"ref144\/cit144","unstructured":"Novartis - Pfizer Collaboration. https:\/\/www.novartis.com\/news\/media-releases\/novartis-announces-clinical-collaboration-pfizer-advance-treatment-nash (accessed Sept 25, 2019)."},{"key":"ref145\/cit145","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20121689"},{"key":"ref146\/cit146","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2011.10.003"},{"key":"ref147\/cit147","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.26.070157.001003"},{"key":"ref148\/cit148","doi-asserted-by":"publisher","DOI":"10.1172\/JCI105660"},{"key":"ref149\/cit149","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.90949.2008"},{"key":"ref150\/cit150","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R800018-JLR200"},{"key":"ref151\/cit151","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.22.13018"},{"key":"ref152\/cit152","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M106219200"},{"key":"ref153\/cit153","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M106168200"},{"key":"ref154\/cit154","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000151874.81059.ad"},{"key":"ref155\/cit155","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M600331-JLR200"},{"key":"ref156\/cit156","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M800494200"},{"key":"ref157\/cit157","doi-asserted-by":"publisher","DOI":"10.1038\/75651"},{"key":"ref158\/cit158","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M311000200"},{"key":"ref159\/cit159","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M704213200"},{"key":"ref160\/cit160","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201402069"},{"key":"ref161\/cit161","doi-asserted-by":"publisher","DOI":"10.1021\/jm4007033"},{"key":"ref162\/cit162","doi-asserted-by":"publisher","DOI":"10.1021\/jm301296t"},{"key":"ref163\/cit163","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12002"},{"key":"ref164\/cit164","unstructured":"Escribano, A. M.; Gonzalez, M. R.; Blanco, C. L.; Finger, M. D. M.O.; Wiley, M. R. Novel DGAT2 Inhibitors. International Patent WO2016187384, 2016."},{"key":"ref165\/cit165","unstructured":"Camp, P. N.; Naik, M. Novel DGAT2 Inhibitors. International Patent WO2015077299, 2015."},{"key":"ref166\/cit166","unstructured":"Boehm, M.; Cabral, S.; Dowling, M. S.; Futatsugi, K.; Huard, K. Diacylglycerol Acyltransferase 2 Inhibitors. International Patent WO2018033832, 2018."},{"key":"ref167\/cit167","unstructured":"O\u2019Gorman, P.; Naimimohasses, S.; Monaghan, A.; Kennedy, M.; Finn, S.; Gormley, J.; Norris, S. An International, Randomized, Placebo-Controlled Phase 2 Trial Demonstrates Novel Effects of DGAT2 Antisense Inhibition in Reducing Steatosis without causing Hypertriglyceridemia in T2DM Patients. Presented at the European Associate for the Study of the Liver International Liver Conference, Vienna, Austria, April 10\u201314, 2019; PS-106."},{"key":"ref168\/cit168","first-page":"69","volume":"1","author":"Liu H.","year":"2010","journal-title":"Int. J. Biochem. Mol. Biol."},{"key":"ref169\/cit169","doi-asserted-by":"publisher","DOI":"10.1021\/jm2005805"},{"key":"ref170\/cit170","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0126"},{"key":"ref171\/cit171","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2016.1245286"},{"key":"ref172\/cit172","doi-asserted-by":"publisher","DOI":"10.1021\/jm2016045"},{"key":"ref173\/cit173","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2011.09.017"},{"key":"ref174\/cit174","first-page":"505","volume":"3","author":"Dorn C.","year":"2010","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref175\/cit175","doi-asserted-by":"crossref","unstructured":"Patel, M.; Infante, J.; Hoff, D. V.; Jones, S.; Burris, H.; Brenner, A.; McCulloch, W.; Zhukova-Harrill, V.; Kemble, G.; Parsey, M. Report of a First-In-Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640. Presented at the 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, USA, April 18\u201322, 2015; CT203.","DOI":"10.1158\/1538-7445.AM2015-CT203"},{"key":"ref176\/cit176","unstructured":"Forma Therapeutics. https:\/\/www.formatherapeutics.com\/pipeline\/ft-4101-ft-8225\/ (accessed Sept 25, 2019)."},{"key":"ref177\/cit177","unstructured":"Beysen, C.; Dole, K.; Schroeder, P.; Brevard, J.; Ribadeneira, M.; Sheth, P.; Mishkin, A.; O\u2019Reilly, T. E. Inhibition of Fatty Acid Synthase (FASN) with FT-4101 Reduces Hepatic De Novo Lipogenesis (DNL) in Healthy Adult Subjects. Presented at the American Association for the Study of Liver Diseases, Boston, USA, November 13\u201317, 2019; 2151."},{"key":"ref178\/cit178","doi-asserted-by":"publisher","DOI":"10.1126\/science.1218099"},{"key":"ref179\/cit179","doi-asserted-by":"publisher","DOI":"10.1126\/science.1218530"},{"key":"ref180\/cit180","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2016.01.017"},{"key":"ref181\/cit181","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12308"},{"key":"ref182\/cit182","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.839659"},{"key":"ref183\/cit183","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061551"},{"key":"ref184\/cit184","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1303360110"},{"key":"ref185\/cit185","doi-asserted-by":"publisher","DOI":"10.1126\/science.1225601"},{"key":"ref186\/cit186","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2018.01.002"},{"key":"ref187\/cit187","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2017.09.002"},{"key":"ref188\/cit188","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29025"},{"key":"ref189\/cit189","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1494153"},{"key":"ref190\/cit190","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.363960"},{"key":"ref191\/cit191","unstructured":"Harrison, S. A.; Neff, G.; Davison, B.; Moussa, S.; Alkhouri, N.; Cusi, K.; Colca, J.; Sanyal, A. J.; Loomba, R.; Cotter, G.; Dittrich, H. Results of MSDC-0602K in a Large Phase 2b NASH Study Demonstrate Improvement in Markers of Insulin Resistance, Glucose Metabolism, Serum Aminotransferases, Non Invasive Markers of NASH and Histopathology. Presented at the American Association for the Study of Liver Diseases, Boston, USA, November 13\u201317, 2019; LO1."},{"key":"ref192\/cit192","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2017.11.002"},{"key":"ref193\/cit193","doi-asserted-by":"publisher","DOI":"10.2741\/3399"},{"key":"ref194\/cit194","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M306370200"},{"key":"ref195\/cit195","doi-asserted-by":"publisher","DOI":"10.1021\/jm0402162"},{"key":"ref196\/cit196","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.038711"},{"key":"ref197\/cit197","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf4823"},{"key":"ref198\/cit198","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-017-0429-7"},{"key":"ref199\/cit199","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.753056"},{"key":"ref200\/cit200","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.13563"},{"key":"ref201\/cit201","doi-asserted-by":"publisher","DOI":"10.3390\/nu6052088"},{"key":"ref202\/cit202","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1079"},{"key":"ref203\/cit203","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04041-1"},{"key":"ref204\/cit204","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/810961"},{"key":"ref205\/cit205","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.05.033"},{"key":"ref206\/cit206","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/3.9.1627"},{"key":"ref207\/cit207","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1119908109"},{"key":"ref208\/cit208","first-page":"197","volume-title":"Nutrition in the Prevention and Treatment of Abdominal Obesity","author":"Schlappal A.","year":"2014"},{"key":"ref209\/cit209","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3678"},{"key":"ref210\/cit210","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0411"},{"key":"ref211\/cit211","doi-asserted-by":"publisher","DOI":"10.1172\/JCI94427"},{"key":"ref212\/cit212","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1942.02010020037004"},{"key":"ref213\/cit213","doi-asserted-by":"publisher","DOI":"10.1021\/jm100677s"},{"key":"ref214\/cit214","doi-asserted-by":"publisher","DOI":"10.1021\/ml200070g"},{"key":"ref215\/cit215","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2011.06.067"},{"key":"ref216\/cit216","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00947"},{"key":"ref217\/cit217","unstructured":"Dowling, M.; Fernando, D.; Futatsugi, K.; Huard, K.; Magee, T. V. Substituted 3-Azabicyclo[3.1.0]hexanes as Ketohexokinase Inhibitors. International Patent WO2017115205, 2017."},{"key":"ref218\/cit218","doi-asserted-by":"crossref","unstructured":"Calle, R.; Bergman, A.; Somayaji, V.; Chisey, K.; Kazierd, D. Ketohexokinase Inhibitor PF-06835919 Administered for 6 Weeks Reduces Whole Liver Fat as Measured by Magnetic Resonance Imaging-Proton Density Fat Fraction in Subjects with Non-Alcoholic Fatty Liver Disease. Presented at the European Associate for the Study of the Liver International Liver Conference, Vienna, Austria, April 10\u201314, 2019; PS-110.","DOI":"10.1016\/S0618-8278(19)30122-7"},{"key":"ref219\/cit219","doi-asserted-by":"publisher","DOI":"10.1210\/endo.134.5.8156917"},{"key":"ref220\/cit220","doi-asserted-by":"publisher","DOI":"10.1210\/endo.137.7.8770921"},{"key":"ref221\/cit221","doi-asserted-by":"publisher","DOI":"10.1369\/jhc.2008.951319"},{"key":"ref222\/cit222","doi-asserted-by":"publisher","DOI":"10.1017\/S146239940900132X"},{"key":"ref223\/cit223","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2013.01.004"},{"key":"ref224\/cit224","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011395"},{"key":"ref225\/cit225","doi-asserted-by":"publisher","DOI":"10.2337\/diab.44.9.1126"},{"key":"ref226\/cit226","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.19.6.580"},{"key":"ref227\/cit227","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.81.1.8550773"},{"key":"ref228\/cit228","doi-asserted-by":"publisher","DOI":"10.1172\/JCI990"},{"key":"ref229\/cit229","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201700781"},{"key":"ref230\/cit230","first-page":"31","volume-title":"Handbook of Incretin-based Therapies in Type 2 Diabetes","author":"Baptist G.","year":"2016"},{"key":"ref231\/cit231","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2017-000554"},{"key":"ref232\/cit232","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2010.12.016"},{"key":"ref233\/cit233","doi-asserted-by":"publisher","DOI":"10.1210\/endo-125-6-3109"},{"key":"ref234\/cit234","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-29087"},{"key":"ref235\/cit235","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.363"},{"key":"ref236\/cit236","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27302013000900005"},{"key":"ref237\/cit237","doi-asserted-by":"publisher","DOI":"10.1021\/jm9909645"},{"key":"ref238\/cit238","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"ref239\/cit239","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2548"},{"key":"ref240\/cit240","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12555"},{"key":"ref241\/cit241","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00726"},{"key":"ref242\/cit242","unstructured":"Gilead - Novo Nordisk Collaboration. https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2019\/4\/gilead-sciences-and-novo-nordisk-announce-intent-to-initiate-a-clinical-collaboration-in-nash (accessed Sept 25, 2019)."},{"key":"ref243\/cit243","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201800699"},{"key":"ref244\/cit244","unstructured":"Mjalli, A. M. M.; Polisetti, D. R.; Yokum, T. S.; Kalpathy, S.; Guzel, M.; Behme, C.; Davis, S. T. Oxadiazoanthracene Compounds for the Treatment of Diabetes. International Patent WO2009111700, 2009."},{"key":"ref245\/cit245","unstructured":"Rao, M. Ligands for the GLP-1 Receptor and Methods for Discovery Thereof. International Patent WO2009126709, 2009."},{"key":"ref246\/cit246","unstructured":"Freeman, J. L. R.; Dunn, I.; Valcarce, C. Preclinical Findings with Oral GLP-1 Receptor Agonist TTP273 Reinforce Importance of Neuro-Enteroendocrine Signaling. Presented at the 76th Scientific Session of the American Diabetes Association, New Orleans, USA, June 10\u201314, 2016; 1177-P."},{"key":"ref247\/cit247","unstructured":"Freeman, J. L. R.; Dunn, I.; Valcarce, C. Beyond Topline Results for the Oral (Non-Peptide) GLP-1R Agonist TTP273 in Type 2 Diabetes: How much and When? Presented at the European Associate for the Study of Diabetes, Lisbon, Portugal, September 11\u201315, 2017; Abstract 112."},{"key":"ref248\/cit248","unstructured":"Freeman, J.; Soeder, T.; Dunn, I.; Valcarce, C. Is Less More? Learning to Dose the Oral, Non-peptide GLP-1R Agonist, TTP273 in Type 2 Diabetics. Presented at the 77th Scientific Session of the American Diabetes Association, San Diego, USA, June 9\u201313, 2017; 168-P."},{"key":"ref249\/cit249","unstructured":"Freeman, J.; Dvergsten, C.; Dunn, I.; Valcarce, C. TTP273, Oral (Nonpeptide) GLP-1R Agonist: Improved Glycemic Control Without Nausea and Vomiting in Phase 2. Presented at the 77th Scientific Session of the American Diabetes Association, San Diego, USA, June 9\u201313, 2017; 1220-P."},{"key":"ref250\/cit250","unstructured":"Yoshino, H.; Tsuchiya, S.; Matsuo, A.; Sato, T.; Nishimoto, M.; Oguri, K.; Ogawa, H.; Nishimura, Y.; Furuta, Y.; Kashiwagi, H.; Hori, N.; Kamon, T.; Shiraishi, T.; Yoshida, S.; Kawai, T.; Tanida, S.; Aoki, M. Pyrazolopyridine Derivative Having GLP-1 Receptor Agonist Effect. International Patent WO2018056453, 2018."},{"key":"ref251\/cit251","doi-asserted-by":"crossref","unstructured":"Kawai, T.; Tanino, F.; Fukazawa, M.; Ogawa, K.; Nagao, S.; Yoshino, H.; Komatsu, S.I.; Suzuki, Y.; Kawabe, Y. OWL833, An Orally Active Nonpeptide GLP-1 Receptor Agonist, Improves Glucose Tolerance by Increasing Insulin Secretion and Reduces Food Intake of Cynomolgus Monkeys. Presented at the  78th Scientific Session of the American Diabetes Association, Orlando, USA, June 22\u201326, 2018; 1118-P.","DOI":"10.2337\/db18-1118-P"},{"key":"ref252\/cit252","unstructured":"Edmonds, D.; Fortin, J.P.; Griffor, M.; Jackson, M.; Kalgutkar, A.; Kuzmiski, J.; Landis, M.; Lettiere, D.; Limberakis, C.; Liras, S.; Loria, P.; Griffith, D.; Mathiowetz, A.; Piotrowski, D.; Price, D.; Stevens, L.; Rolph, T.; Ruggeri, R.; Saxena, A.; Smith, A.; Tess, D.; Wei, L.; Bagley, S.; Buckeridge, C.; Conn, E.; Curto, J.; Derksen, D.; Eng, H.; Flanagan, M.; Discovery of PF-06882961: A Potent, Orally Bioavailable Small Molecule Agonist of The GLP-1 Receptor. In  257th American Chemical Society National Meeting & Exposition, Orlando, USA, March 31\u2013April 4, 2019; MEDI 274."},{"key":"ref253\/cit253","volume-title":"17th Annual Discovery on Target","author":"Griffith D. A.","year":"2019"},{"key":"ref254\/cit254","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.532"},{"key":"ref255\/cit255","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0642"},{"key":"ref256\/cit256","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.2001.280.1.F10"},{"key":"ref257\/cit257","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.20.452"},{"key":"ref258\/cit258","doi-asserted-by":"publisher","DOI":"10.1038\/350354a0"},{"key":"ref259\/cit259","doi-asserted-by":"publisher","DOI":"10.1038\/ng0296-216"},{"key":"ref260\/cit260","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-002-0820-5"},{"key":"ref261\/cit261","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04010609"},{"key":"ref262\/cit262","doi-asserted-by":"publisher","DOI":"10.1016\/S0925-4439(98)00109-4"},{"key":"ref263\/cit263","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0081"},{"key":"ref264\/cit264","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000311"},{"key":"ref265\/cit265","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2017-0241"},{"key":"ref266\/cit266","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-014-0089-4"},{"key":"ref267\/cit267","doi-asserted-by":"publisher","DOI":"10.1021\/jm990175n"},{"key":"ref268\/cit268","unstructured":"Ellsworth, B.; Washburn, W. N.; Sher, P. M.; Meng, W. C-Aryl Glucoside SGLT2 Inhibitors. International Patent WO2001027128, 2001."},{"key":"ref269\/cit269","doi-asserted-by":"publisher","DOI":"10.1021\/jm100332n"},{"key":"ref270\/cit270","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13304"},{"key":"ref271\/cit271","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.294"},{"key":"ref272\/cit272","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S184767"},{"key":"ref273\/cit273","doi-asserted-by":"publisher","DOI":"10.1021\/jm701272q"},{"key":"ref274\/cit274","unstructured":"Jikura, H.; Fushimi, N.; Nishimura, T.; Tatani, K.; Katsuno, K. Glucopyranosyloxy Benzylbenzene Derivatives, Medicinal Compositions Containing the Same and Intermediates for the Preparation of the Derivatives. International Patent WO2001068660, 2001."},{"key":"ref275\/cit275","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2018.33.3.387"},{"key":"ref276\/cit276","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2017.07.002"},{"key":"ref277\/cit277","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13520"},{"key":"ref278\/cit278","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01517.x"},{"key":"ref279\/cit279","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-019-5477-1"},{"key":"ref280\/cit280","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165"},{"key":"ref281\/cit281","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2012.03.051"},{"key":"ref282\/cit282","doi-asserted-by":"publisher","DOI":"10.1021\/jm901893x"},{"key":"ref283\/cit283","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13061"},{"key":"ref284\/cit284","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13236"},{"key":"ref285\/cit285","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1107"},{"key":"ref286\/cit286","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.04.038"},{"key":"ref287\/cit287","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0401627101"},{"key":"ref288\/cit288","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2007.10.014"},{"key":"ref289\/cit289","unstructured":"Ratziu, V.; Guevara, L. d.; Safadi, R.; Poordad, F.; Fuster, F.; Flores-Figueroa, J.; Harrison, S. A.; Arrese, M.; Fargion, S.; Bashat, D. B.; Lackner, C.; Gorfine, T.; Kadosh, S.; Oren, R.; Loomba, R.; Sanyal, A. J. One-Year Results of the Global Phase 2b Randomized Placebo Controlled Arrest Trial of Aramchol, a Stearoyl CoA Desaturase Modulator in NASH Patients. Presented at the American Association for the Study of Liver Diseases, San Francisco, USA, November 9\u201313, 2018; LB-5."},{"key":"ref290\/cit290","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2007.08.011"},{"key":"ref291\/cit291","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00227-07"},{"key":"ref292\/cit292","doi-asserted-by":"publisher","DOI":"10.1021\/bi100010j"},{"key":"ref293\/cit293","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1620813114"},{"key":"ref294\/cit294","doi-asserted-by":"publisher","DOI":"10.1021\/jm200117h"},{"key":"ref295\/cit295","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2012.09.022"},{"key":"ref296\/cit296","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2012.10.084"},{"key":"ref297\/cit297","doi-asserted-by":"publisher","DOI":"10.1002\/pro.2298"},{"key":"ref298\/cit298","doi-asserted-by":"crossref","unstructured":"Budas, G. K. S.; Jonnson, T.; Shafizadeh, T.; Watkins, S.; Breckenridge, D.; Tumas, D. Reduction of Liver Steatosis and Fibrosis with an ASK1 Inhibitor in a Murine Model of Nash is Accompanied by Improvements in Cholesterol, Bile Acid and Lipid Metabolism. Presented at the European Associate for the Study of the Liver International Liver Conference, Barcelona, Spain, April 13\u201317, 2016; PS070.","DOI":"10.1016\/S0168-8278(16)01686-X"},{"key":"ref299\/cit299","unstructured":"Notte, G. Apoptosis Signal-Regulating Kinase Inhibitor. International Patent WO2013112741, 2013."},{"key":"ref300\/cit300","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.6b00481"},{"key":"ref301\/cit301","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99768"},{"key":"ref302\/cit302","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29514"},{"key":"ref303\/cit303","doi-asserted-by":"crossref","unstructured":"Lawitz, E.; Herring, R.; Younes, Z. H.; Gane, E.; Ruane, P. J.; Aguilar, R.; Jia, C.; Xu, R.; McColgan, B.; Djedjos, C. S.; Subramanian, G. M.; McHutchison, J. G.; Myers, R. P.; Middleton, M.; Li, K.; Hellerstein, M.; Kwo, P.; Noureddin, M.; Harrison, S. A. Proof-of-Concept Study of an Apoptosis-Signal Regulating Kinase (ASK1) Inhibitor (Selonsertib) in Combination with an Acetyl-CoA Carboxylase Inhibitor (GS-0976) or a Farnesoid X Receptor (FXR) Agonist (GS-9674) in NASH. Presented at the European Association for the Study of the Liver International Liver Conference, Paris, France, April 11\u201315, 2018; PS-105.","DOI":"10.1016\/S0168-8278(18)30335-0"},{"key":"ref304\/cit304","unstructured":"Gilead https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2019\/12\/gilead-announces-topline-results-from-phase-2-atlas-study-in-patients-with-bridging-fibrosis-f3-and-compensated-cirrhosis-f4-due-to-nonalcoholic-s (accessed Dec 18, 2019)."},{"key":"ref305\/cit305","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.020"},{"key":"ref306\/cit306","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.68.1.383"},{"key":"ref307\/cit307","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20041142"},{"key":"ref308\/cit308","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.3.3.391"},{"key":"ref309\/cit309","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2014.7"},{"key":"ref310\/cit310","doi-asserted-by":"publisher","DOI":"10.2174\/156802605775009720"},{"key":"ref311\/cit311","doi-asserted-by":"publisher","DOI":"10.1021\/jm050307e"},{"key":"ref312\/cit312","unstructured":"Conatus Collaboration https:\/\/www.conatuspharma.com\/partnerships (accessed Sept 25, 2019)."},{"key":"ref313\/cit313","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(03)00755-8"},{"key":"ref314\/cit314","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12570"},{"key":"ref315\/cit315","unstructured":"Harrison, S. A.; Goodman, Z. D.; Jabbar, A.; Younes, Z.; Vemulapalli, R.; Freilich, B. L.; Sheikh, M. Y.; Schattenberg, J.; Kayali, Z.; Zivony, A. S.; Sheikh, A. M.; Garcia-Samaniego, J.; Satapathy, S. K.; Therapondos, G.; Mena, E. A.; Schuppan, D.; Robinson, J. M.; Chan, J. L.; Hagerty, D.; Sanyal, A. J. A Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial of Emricasan in Subjects with Nonalcoholic Steatohepatitis (NASH) and Fibrosis. Presented at the European Associate for the Study of the Liver International Liver Conference, Vienna, Austria, April 10\u201314, 2019; 61."},{"key":"ref316\/cit316","unstructured":"Conatus https:\/\/www.globenewswire.com\/news-release\/2019\/06\/24\/1873299\/0\/en\/Conatus-Announces-Results-from-ENCORE-LF-and-ENCORE-PH-Phase-2b-Clinical-Trials-in-NASH-Cirrhosis.html (accessed Sept 25, 2019)."},{"key":"ref317\/cit317","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.06.043"},{"key":"ref318\/cit318","doi-asserted-by":"publisher","DOI":"10.1172\/JCI26498"},{"key":"ref319\/cit319","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24335"},{"key":"ref320\/cit320","doi-asserted-by":"publisher","DOI":"10.2337\/db11-1506"},{"key":"ref321\/cit321","doi-asserted-by":"publisher","DOI":"10.1042\/CS20110515"},{"key":"ref322\/cit322","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.080632"},{"key":"ref323\/cit323","doi-asserted-by":"publisher","DOI":"10.1172\/JCI37444"},{"key":"ref324\/cit324","doi-asserted-by":"publisher","DOI":"10.1021\/jm9906264"},{"key":"ref325\/cit325","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2004.10.021"},{"key":"ref326\/cit326","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.52.818"},{"key":"ref327\/cit327","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.52.577"},{"key":"ref328\/cit328","doi-asserted-by":"publisher","DOI":"10.1021\/jm0509703"},{"key":"ref329\/cit329","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1442436"},{"key":"ref330\/cit330","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158156"},{"key":"ref331\/cit331","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2016.02.012"},{"key":"ref332\/cit332","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29477"},{"key":"ref333\/cit333","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c130044"},{"key":"ref334\/cit334","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000118519.66430.22"},{"key":"ref335\/cit335","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000159937.05502.d1"},{"key":"ref336\/cit336","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e3283391989"},{"key":"ref337\/cit337","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2006.03.007"},{"key":"ref338\/cit338","first-page":"650","volume":"240","author":"de Gasparo M.","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref339\/cit339","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00419.2013"},{"key":"ref340\/cit340","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12794"},{"key":"ref341\/cit341","unstructured":"Iijima, T.; Yamamoto, Y.; Akatsuka, H.; Kawaguchi, T. Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents. International Patent WO2007089034, 2007."},{"key":"ref342\/cit342","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65514-9"},{"key":"ref343\/cit343","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.6.2255"},{"key":"ref344\/cit344","doi-asserted-by":"publisher","DOI":"10.1126\/science.1529341"},{"key":"ref345\/cit345","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-004-1346-2"},{"key":"ref346\/cit346","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2009.01.027"},{"key":"ref347\/cit347","doi-asserted-by":"publisher","DOI":"10.3109\/10408363.2015.1050714"},{"key":"ref348\/cit348","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2017.7418"},{"key":"ref349\/cit349","doi-asserted-by":"publisher","DOI":"10.1172\/JCI73722"},{"key":"ref350\/cit350","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2011.594040"},{"key":"ref351\/cit351","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-015-0200-z"},{"key":"ref352\/cit352","doi-asserted-by":"publisher","DOI":"10.1021\/jm8011867"},{"key":"ref353\/cit353","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2012.04.111"},{"key":"ref354\/cit354","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.207613"},{"key":"ref355\/cit355","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27551-6"},{"key":"ref356\/cit356","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2018.03.001"},{"key":"ref357\/cit357","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13573"},{"key":"ref358\/cit358","unstructured":"Boehringer\nIngelheim http:\/\/www.pharmaxis.com.au\/investor-centre\/news\/view\/boehringer-ingelheim-discontinues-development-of-bi-1467335-for-nash (accessed Dec 18, 2019)."},{"key":"ref359\/cit359","unstructured":"Terns\nPharmaceuticals: TERN-201. https:\/\/www.ternspharma.com\/8-13-19-terns-announces-positive-interim-results-from-ongoing-phase-1-clinical-trial-of-tern-201 (accessed Sept 25, 2019)."},{"key":"ref360\/cit360","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2013.12.022"},{"key":"ref361\/cit361","doi-asserted-by":"publisher","DOI":"10.1038\/srep10568"},{"key":"ref362\/cit362","doi-asserted-by":"publisher","DOI":"10.1016\/S0945-053X(98)90012-9"},{"key":"ref363\/cit363","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01247.x"},{"key":"ref364\/cit364","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2015.05.005"},{"key":"ref365\/cit365","doi-asserted-by":"publisher","DOI":"10.1186\/1755-1536-7-4"},{"key":"ref366\/cit366","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.53"},{"key":"ref367\/cit367","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29085"},{"key":"ref368\/cit368","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2014.07.003"},{"key":"ref369\/cit369","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2208"},{"key":"ref370\/cit370","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312473"},{"key":"ref371\/cit371","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2018.1550649"},{"key":"ref372\/cit372","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20071634"},{"key":"ref373\/cit373","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.006"},{"key":"ref374\/cit374","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30237"},{"key":"ref375\/cit375","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-009-9252-8"},{"key":"ref376\/cit376","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00345"},{"key":"ref377\/cit377","unstructured":"Pharmakea Therapeutics http:\/\/www.pharmakea.com\/index.php?%20option=com_content&view=article&id=41&Itemid=231 (accessed Sept 25, 2019)."},{"key":"ref378\/cit378","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14074"},{"key":"ref379\/cit379","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01283"},{"key":"ref380\/cit380","first-page":"4849","volume":"34","author":"Takakura K.","year":"2014","journal-title":"Anticancer Res."},{"key":"ref381\/cit381","unstructured":"Pharmaxis http:\/\/www.pharmaxis.com.au\/product-pipeline\/amine-oxidase-platform\/loxloxl2\/ (accessed Sept 25, 2019)."},{"key":"ref382\/cit382","doi-asserted-by":"publisher","DOI":"10.1021\/bi201121m"},{"key":"ref383\/cit383","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.208884"},{"key":"ref384\/cit384","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020392"},{"key":"ref385\/cit385","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990517)81:4<519::AID-IJC3>3.0.CO;2-0"},{"key":"ref386\/cit386","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0511167103"},{"key":"ref387\/cit387","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00257.2011"},{"key":"ref388\/cit388","doi-asserted-by":"crossref","unstructured":"Chalasani, N.; Garcia-Tsao, G.; Goodman, Z.; Lawitz, E.; Abdelmalek, M.; Rinella, M.; Ryan, M.; Noureddin, M.; Jue, C.; Pyko, M.; Allgood, A.; Shlevin, H.; Horton, R.; Zomer, E.; Traber, P.; Loomba, R.; Tetri, B.; Sanyal, A.; Harrison, S. A Multicenter, Randomized, Double-Blind, PLB-Controlled Trial of Galectin-3 Inhibitor (GR-MD-02) in Patients with NASH Cirrhosis and Portal Hypertension. Presented at the European Associate for the Study of the Liver International Liver Conference, Paris, France, April 11\u201315, 2018; LBO-001.","DOI":"10.1016\/S0168-8278(18)30420-3"},{"key":"ref389\/cit389","unstructured":"Galaectin Therapeutics https:\/\/investor.galectintherapeutics.com\/news-releases\/news-release-details\/galectin-therapeutics-proceeds-phase-3-development-gr-md-02-nash (accessed Sept 25, 2019)."},{"key":"ref390\/cit390","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2017.06.007"},{"key":"ref391\/cit391","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v8.i16.673"},{"key":"ref392\/cit392","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4354-8"},{"key":"ref393\/cit393","unstructured":"Boehringer\nIngelheim - Yuhan https:\/\/www.boehringer-ingelheim.com\/press-release\/collaboration-yuhan-corporation-nash (accessed Dec 18, 2019)."},{"key":"ref394\/cit394","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1821045116"},{"key":"ref395\/cit395","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2012.04.002"},{"key":"ref396\/cit396","unstructured":"Pliant https:\/\/www.prnewswire.com\/news-releases\/pliant-therapeutics-announces-strategic-collaboration-to-develop-novel-therapies-for-nash-and-fibrotic-diseases-300942572.html (accessed Nov 26, 2019)."},{"key":"ref397\/cit397","unstructured":"Morphic - Abbvie https:\/\/www.prnewswire.com\/news-releases\/abbvie-and-morphic-therapeutic-announce-collaboration-targeting-fibrotic-diseases-300733319.html (accessed Nov 26, 2019)."},{"key":"ref398\/cit398","unstructured":"Morphic - Janssen https:\/\/morphictx.com\/2019\/02\/21\/morphic-therapeutic-enters-into-integrin-research-and-development-collaboration-with-janssen\/ (accessed Nov 26, 2019)."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.9b01701","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T01:51:17Z","timestamp":1682560277000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.jmedchem.9b01701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":398,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,5,28]]}},"alternative-id":["10.1021\/acs.jmedchem.9b01701"],"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01701","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]}}}